MX2024008273A - Composiciones y metodos para el tratamiento de la enfermedad de huntington. - Google Patents

Composiciones y metodos para el tratamiento de la enfermedad de huntington.

Info

Publication number
MX2024008273A
MX2024008273A MX2024008273A MX2024008273A MX2024008273A MX 2024008273 A MX2024008273 A MX 2024008273A MX 2024008273 A MX2024008273 A MX 2024008273A MX 2024008273 A MX2024008273 A MX 2024008273A MX 2024008273 A MX2024008273 A MX 2024008273A
Authority
MX
Mexico
Prior art keywords
disease
methods
compositions
treating huntington
subject
Prior art date
Application number
MX2024008273A
Other languages
English (en)
Spanish (es)
Inventor
Ted Yednock
Ann Mongan
Ellen Cahir-Mcfarland
Original Assignee
Annexon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Annexon Inc filed Critical Annexon Inc
Publication of MX2024008273A publication Critical patent/MX2024008273A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4716Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2835Movement disorders, e.g. Parkinson, Huntington, Tourette
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pathology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2024008273A 2021-12-30 2022-12-29 Composiciones y metodos para el tratamiento de la enfermedad de huntington. MX2024008273A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163295213P 2021-12-30 2021-12-30
US202263349305P 2022-06-06 2022-06-06
PCT/US2022/082523 WO2023130001A1 (en) 2021-12-30 2022-12-29 Compositions and methods for treating huntington's disease

Publications (1)

Publication Number Publication Date
MX2024008273A true MX2024008273A (es) 2024-07-19

Family

ID=87000332

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024008273A MX2024008273A (es) 2021-12-30 2022-12-29 Composiciones y metodos para el tratamiento de la enfermedad de huntington.

Country Status (8)

Country Link
US (1) US20250074973A1 (cg-RX-API-DMAC7.html)
EP (1) EP4457244A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025503545A (cg-RX-API-DMAC7.html)
KR (1) KR20240126863A (cg-RX-API-DMAC7.html)
AU (1) AU2022425559A1 (cg-RX-API-DMAC7.html)
IL (1) IL313901A (cg-RX-API-DMAC7.html)
MX (1) MX2024008273A (cg-RX-API-DMAC7.html)
WO (1) WO2023130001A1 (cg-RX-API-DMAC7.html)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3019240T3 (da) * 2013-07-09 2024-06-03 Annexon Inc Anti-komplementfaktor C1Q antistoffer og anvendelser deraf
EP3380518B1 (en) * 2015-11-24 2026-03-25 Annexon, Inc. Anti-complement factor c1q fab fragments and uses thereof
GB2584105B (en) * 2019-05-21 2023-08-02 Argenx Bvba Methods of treating neuropathy

Also Published As

Publication number Publication date
EP4457244A4 (en) 2026-01-07
EP4457244A1 (en) 2024-11-06
US20250074973A1 (en) 2025-03-06
JP2025503545A (ja) 2025-02-04
AU2022425559A1 (en) 2024-07-04
IL313901A (en) 2024-08-01
KR20240126863A (ko) 2024-08-21
WO2023130001A1 (en) 2023-07-06

Similar Documents

Publication Publication Date Title
PH12021551734A1 (en) Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders
NO20034549L (no) Behandling av type 2 diabetes med inhibitorer av dipeptidyl peptidase IV
NO962568L (no) Anvendelse av PLA2 inhibitorer som behandling for Alzheimers sykdom
BR0304648A (pt) Combinação de inibidores de ciclooxigenase-2 e talidomida para o tratamento de neoplasia
EA202092750A1 (ru) Соединения ингибиторы vmat2, композиции и способы, относящиеся к ним
WO2022047128A3 (en) Method for treating complement mediated disorders caused by betacoronaviruses
BR112022022578A2 (pt) Novas composições e métodos de tratar doença covid-19
ECSP20082339A (es) Moduladores de la expresión de apol1
MX2024003120A (es) Metodos y composiciones que comprenden anticuerpos anti-cd3 e inhibidores de dyrk1a para tratar la diabetes.
WO2022081813A3 (en) Enhanced scale inhibitor squeeze treatment using a chemical additive
ZA202106809B (en) Medium chain triglyceride formulations with improved bioavailiblity and methods related thereto
MX2024014121A (es) Metodos y composiciones para el tratamiento del exceso de glucocorticoides
MX2022010258A (es) Composiciones y métodos para tratar la lesión renal.
MX2022011725A (es) Metodos para tratar una lesion pulmonar con inhibidores de cgrp.
WO2023055885A3 (en) Ezh2 inhibition in pancreatic cancer
MX2024015763A (es) Composiciones y metodos para inhibir la expresion de serina proteasa transmembrana 6 (tmprss6)
MX2022012632A (es) Uso de inhibidores del bromodominio para el tratamiento de la enfermedad de huntington.
MX2024008273A (es) Composiciones y metodos para el tratamiento de la enfermedad de huntington.
CA3242780A1 (en) Compositions and methods for treating huntington's disease
MX2022013927A (es) Composiciones y metodos para tratar la epilepsia.
WO2023147513A3 (en) Compositions of autophagy modulating agents and uses thereof
CL2022002317A1 (es) Métodos para tratar esclerosis múltiple progresiva primaria usando un inhibidor de tirosina quinasa de bruton.
WO2025030161A8 (en) Rexinoids for treatment of ocular diseases
PH12022552645A1 (en) Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
FR3108031B1 (fr) Utilisation de NMN pour la prévention et/ou le traitement d’une douleur dorsale et compositions correspondantes